PCI and ACS: Where do Vorapaxar vorapaxar and bivalirudin fit in? June 01, 2015 Overview Show transcript Overview Naveen L. Pereira, M.D., assistant professor of medicine and pharmacology, and Gurpreet S. Sandhu, M.D., Ph.D., director of the Cardiac Catheterization Laboratory at Mayo Clinic's campus in Rochester, Minnesota, discuss adjunctive pharmacotherapy and coronary artery disease, with an emphasis on anticoagulation and antiplatelet drugs. Share Doximity Facebook LinkedIn Twitter Print details Receive Mayo Clinic news in your inbox. Sign up Related ContentVideoLessons from China on critical care considerations and staff safety during COVID-19ArticleGenetic-guided testing for blood thinner drugs offers patients individualized treatment VID-20433461 Medical Professionals PCI and ACS: Where Do Vorapaxar and Bivalirudin Fit In?